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Abstract: Rapid methodological advances in statistical and computational genomics have enabled
researchers to better identify and interpret both rare and common variants responsible for complex
human diseases. As we continue to see an expansion of these advances in the field, it is now
imperative for researchers to understand the resources and methodologies available for various data
types and study designs. In this review, we provide an overview of recent methods for identifying
rare and common variants and understanding their roles in disease etiology. Additionally, we
discuss the strategy, challenge, and promise of gene therapy. As computational and statistical
approaches continue to improve, we will have an opportunity to translate human genetic findings
into personalized health care.
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1. Introduction
Over the past decade, genome sequencing technology has been one of the fastest
growing fields in biomedical science. Thanks to the progress in sequencing automation, the
cost of sequencing has dropped dramatically. As a result, an enormous amount of genomic
data has been generated, providing an informative profiling of human genetic variations,
disease-related mutations, and association between genotype and phenotype [1–4].
With the achievement of the Human Genome Project and the HapMap Project in the
early 2000s, human genetic research in complex diseases started a new chapter: genomewide association studies (GWAS). In 2005, a landmark GWAS found two single nucleotide
polymorphisms (SNPs) associated with age-related macular degeneration [5]. Later, GWAS
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2. Rare Variant Analysis in Unrelated Individuals
A major challenge in rare variant analyses for complex traits is the limited statistical
power to identify individual variant associations due to the low allele counts. For example,
given a balanced case-control study of 3 K subjects (1.5 K cases vs. 1.5 K controls) at
a type I error α of 5 × 10−8 and a relative risk of 3, the power to detect a variant with
minor allele frequency (MAF) equal to 0.5% is around 0.05. To boost statistical power,
most rare-variant association methods combine association signals across multiple rare
variants in pre-defined variant sets (e.g., genes, genomic regions, pathways, and functional
annotations) and generally assume the presence of multiple trait-associated variants in the
same variant set [13]. We note several popular methods below.
The combined multivariate and collapsing (CMC) test is one of the first methods
to empower rare variant association analysis by collapsing all rare variants into a single
test [14]. A later study introduced the variable threshold (VT) method, which improves
statistical power by dynamically selecting the optimal MAF cutoff that distinguishes
causal rare variants from nonfunctional variants with higher allele frequencies [15]. The
development of the sequence kernel association test (SKAT) is particularly important
because it allows for the incorporation of covariates and can also consider rare variants with
opposite effect directions [16]. Other methods for studying the rare variant associations,
including the cohort allelic sums test (CAST) [17], weighted sum test (WST) [18], the
kernel-based adaptive clustering method (KBAC) [19], the versatile gene-based association
study (VEGAS) [20], the gene-based association test that uses extended Simes procedure
(GATES) [21], the multivariate association analysis using score statistics (MAAUSS) [22],
and multi-trait analysis of rare-variant associations (MTAR) [23], have since been developed
with subtle nuance in their algorithms. A summary of these methods is shown in Table 1.
We also note that study designs, inference algorithms, and statistical details of many
approaches have been extensively reviewed by Lee et al. [24].
Table 1. Statistical approaches for population-based or family-based rare variant analyses.
Type

Methods
Combined Multivariate
and Collapsing
(CMC) test

Strengths
-

Variable
Threshold (VT)
Rare
variant
analysis in
unrelated
individuals

-

Sequence kernel
association test (SKAT)

-

Cohort allelic sums
test (CAST)

More powerful and robust for
analyzing a set of rare variants
than testing each
variant individually
Makes no assumption about
the causal variant’s
allele frequency
Boosts power using functional
annotations that give higher
weights to functional variants
Considers rare variants with
opposite effect directions
Test statistics have a closed
form approximation for their
null distribution
Computationally efficient
Can adjust for covariates
More powerful and robust for
analyzing a set of rare variants
than testing each
variant individually

Weaknesses
-

-

-

-

-

Ref.

Reduced power when the
grouped variants have
effects in opposite directions

[14]

Reduced power when the set
of variants grouped together
have effects in
opposite directions
High computational burden
for permutation test

[15]

Less powerful when causal
variants have the same
effect direction

[16]

Reduced power when the
grouped variants have
effects in opposite directions

[17]
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Table 1. Cont.
Type

Methods
Weighted sum
test (WST)
Kernel-based adaptive
clustering
method (KBAC)
Versatile gene-based
association study
(VEGAS)

Strengths
-

-

-

Gene-based association
test that uses extended
Simes procedure
(GATES)

-

Multivariate
Association Analysis
using Score Statistics
(MAAUSS)

-

Multi-trait analysis of
rare-variant
associations (MTAR)

-

DeNovoWEST
De novo
variants
analysis

Chimpanzee–human
divergence model

-

Has higher statistical power in
the presence of
variant interaction

-

Only uses summary statistics
as input
Can account for LD
between variants

-

Only uses summary statistics
as input
Can account for LD
between variants
Variants can have opposite
effect directions
Computationally efficient
Leverages multiple
phenotypes to improve
statistical power
Improved statistical power in
multi-trait multi-variant
association analysis
Only uses summary statistics
as input
Estimates positive predictive
values of each DNV being
pathogenic
Incorporates a gene-based
weighting strategy
Estimates the relative
locus-specific rates of DNVs

-

Adjusts for sequence depth
and the divergences based on
human–chimp differences
Does not require any control
samples for comparison

Autosomal
recessive
variant
analysis

Can account for linkage
disequilibrium (LD)
between variants

-

denovolyzeR

Resampling-based
statistical framework
-

Weaknesses

Leverages trio data to compare
the observed number of
recessive genotypes with the
empirically estimated counts
under the null
Accounts for confounding due
to population stratification
and consanguinity

Ref.

Lower statistical power
given few causal variants
within a gene

[18]

No closed form null
distribution for test statistics
High computational burden

[19]

Less powerful for detecting a
large gene with many typed
non- causal variants
High computational burden

[20]

Designed for genome-wide
association studies (GWAS)
and has lower power in rare
variant analysis

[21]

-

High computational burden

[22]

-

Relies on a concordant
common and rare variant
genetic correlation
between traits

[23]

-

Limited to exome

[4]

-

Can only be applied to a
selected candidate gene set

[25]

-

Relies on a pre-computed
tabulation of the probability
of DNVs arising in each gene
Limited to exome

[26]

Limited to exome
Strong assumption that all
subjects’ genotypes
are independent

[27]

-

-

-

-
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Table 1. Cont.
Type

Methods

Strengths
-

Sampling the observed
genotypes and
phenotypes by chance

-

-

The phased
haplotypes-based
framework

-

Transmission and de
novo association test
(TADA), extTADA

Joint analysis
of transmitted
variants and
DNVs

-

TADA-Annotations
(TADA-A)
TADA-Recessive
(TADA-R)

Multi-trait TADA
(M-TADA)

-

Various XCI modes
integrated
statistical approach

-

X-linked
variant
analysis

Incorporates the probabilities
of sampling the observed
genotypes and phenotypes
by chance
Incorporates the phenotypic
similarity of patients with the
same recessive candidate gene
Corrects for gene-specific
levels of autozygosity
Takes account of
population structure
Uses the phased haplotypes
from unaffected parents to
estimate the expected number
of biallelic genotypes in
affected probands
Accounts for the fact that some
fraction of the variants
expected by chance are
actually causal
TADA is the first method
developed to jointly model de
novo and transmitted
mutations by a hierarchical
Bayesian modeling framework
extTADA performs a Markov
chain Monte Carlo for the
Bayesian analysis
Can combine information on
all DNVs in both coding and
nearby non-coding regions
across studies
Can integrate signals from
DNVs, transmitted dominant,
and transmitted
recessive variants
Can jointly analyze DNVs
from multiple traits
Considers all X-linked
processes (random, skewed,
and escaped XCI)
Performs a permutation-based
procedure to assess the
significance with
well-controlled type I
error rate

Weaknesses
-

Limited to exome
Requires systematic
genotype and phenotype
data on a known number
of families
Difficult to perform when
recording of phenotype
terms is incomplete
and inconsistent

[28]

Limited to exome
Strong assumption that all
subjects’ genotypes
are independent
Strong assumption of full
penetrance of all genotypes

[29]

-

Both are limited to exome
Both cannot incorporate
recessive genotypes and
model across disease traits

[30,31]

-

Cannot incorporate
transmitted variants

[32]

-

Limited to exome

[33]

-

Limited to exome
Cannot incorporate
transmitted variants
Can only perform
pair-wise comparison

[34]

Has lower power in the
random or escaped XCI test
Cannot provide accurate
effect size estimate in the
escaped XCI model

[35]

False assumption of equal
phenotypic effects between
males’ hemizygotes and
females’ homozygotes
Does not consider
nonrandom XCI and escape
from XCI

[36]

-

-

-

-

-

1 and 2
degree-of-freedom tests
for association

-

Easy to implement using the
contingency table approach

Ref.

-
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Table 1. Cont.
Type

Methods

Strengths
-

Distinct XCI processes
combined using a
modified
Fisher’s method

-

Considers all X-linked
processes (random, skewed,
and escaped XCI)
Is the most statistically efficient
and not sensitive to the
unknown biological models

Weaknesses
-

-

Sex-specific
burden analyses

-

The genetic
linkage method

-

Can estimate the fraction of
probands attributable to rare
X-linked variants
Takes account of phenocopies
and reduced penetrance
Able to deal with
allelic heterogeneity
Able to identify rare alleles
that are present in small
numbers of families

-

-

The candidate
gene approach

Digenic
variant
analysis

-

Case-only
study design

-

-

Useful as the first step in
exploring known pathways in
complex diseases
Offers high statistical power
and is
computationally efficient

No need for
control recruitment
Improved statistical power
compared to the
case–control design
Less multiple-testing correction

-

-

-

Random
forests

-

-

Broad applications in data
mining and machine learning
Flexible and powerful
statistical learning tools
for analysis
Relatively fast and can handle
big GWAS

-

-

Ref.

Strong assumption that all
subjects’ genotypes
are independent
Cannot adjust for covariates

[37]

Strong assumption of a
monogenic model with
full penetrance
Wide confidence intervals for
several key parameters

[38]

Requires pedigrees of related
individuals (and
parents’ samples)
Not suitable for common or
complex-trait diseases
Unable to deal with high
dimensional data and
non-linear regression tests

[39]

Subjective in the process of
choosing specific
candidate genes
Lack of replication studies
Relies on prior hypotheses
about disease mechanisms
Unable to deal with high
dimensional data and
non-linear regression tests

[40]

Potential increase in type I
error rate if the
independence assumption
is violated
Unable to deal with high
dimensional data and
non-linear regression tests

[41]

Sensitive to insufficient
training data, confounding
effects, reproducibility,
and accessibility
Potential slow-performing
algorithm when dealing with
large data set
Requires much
computational power
and resources

[42]

Association analysis methods are ordered and grouped by different types of genetic variants. Each method for
certain types of genetic variants is listed in middle column. The references are indicated in the last column.

3. Rare Variant Analysis for Family-Based Studies
Family-based association analysis has become increasingly popular in sequencing
studies because it provides an opportunity to identify genetic variants that complement
the findings in studies of unrelated individuals. The ability to determine whether genetic
variants segregate with disease status within families helps distinguish causal variants
from non-causal variants [43]. The trio-based study design makes it possible to distinguish
between de novo variants (DNVs) and transmitted variants [44,45]. Finally, family-based
designs can employ both between- and within-family comparisons in a two-step analysis
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to increase statistical power while staying robust to population stratification and other
confounding factors [46–49].
3.1. De Novo Variant
Spontaneously arising DNVs—those present in proband but absent in parents—play
an important role in the pathogenesis of rare congenital diseases such as congenital heart
disease [27,45,50,51]. On average, every subject carries one DNV affecting the proteincoding region of the genome [52,53]. However, modeling DNVs has proven to be challenging because DNVs are not distributed equally across the genome and the sequencing
depth and distribution vary across sequencing platforms when combining samples from
different cohorts.
Several nuanced approaches have been developed to address these issues (Table 1).
The O’Roak study was the first to estimate the relative locus-specific rates of DNV by
incorporating locus-specific transition, transversion, and indel rates, gene length, and a
null expectation based on chimpanzee–human genome differences. However, one major
limitation of this approach is that it can only be applied to a selected candidate gene set [25].
To overcome this limitation and more broadly estimate the mutation rates, Samocha et al.
developed a de novo expectation model to quantify the mutation rates based on trinucleotide sequence contexts and functional annotations, while adjusting for sequence depth
and the divergences based on human–chimp differences [54]. Importantly, this method
does not require any control samples for comparison, but instead quantifies the enrichment
of synonymous DNVs as a negative control group. Furthermore, this Poisson testing
framework for DNV enrichment can yield high statistical power that is difficult to achieve
in case–control analysis. An R package called “denovolyzeR” was developed to implement
this statistical framework [26].
More recently, Kaplanis et al. developed a method named DeNovoWEST to detect
gene-specific enrichments of damaging DNVs. DeNovoWEST is a simulation-based approach that scores all classes of variants on a unified, empirically estimated severity scale
quantifying pathogenicity [4]. Compared with denovolyzeR, DeNovoWEST incorporates
a gene-based weighting strategy derived from the deficit of protein truncating variants
in the general population (e.g., pLI scores) [55]. In the future, incorporation of functional
genomic information (e.g., gene expression in disease-relevant tissues) and other variant
prioritization metrics may further improve the performance of risk gene identification.
3.2. Autosomal Recessive Variant Analysis
To analyze recessive variants that include both homozygous and compound heterozygous variants, a case–control burden test can be performed. However, the challenge in
case–control analysis lies in the often distinct ethnic composition and variable degrees
of consanguinity (i.e., marriage between closely related relatives) across study cohorts or
between cases and controls. Further, it is difficult to establish genome-wide significant
associations in case–control comparisons when studying ultra-rare recessive genotypes due
to limited statistical power [27].
Several analytical strategies have been developed to address these issues (Table 1).
Nadia et al. developed a statistical approach that incorporated the probabilities of sampling
the observed genotypes and phenotypes by chance and applied it to a cohort of 4125 families
with rare and genetically heterogeneous developmental disorders to identify four novel
autosomal recessive disorders [28]. Another study, by Jin et al., developed a resamplingbased statistical framework that leverages trio data to compare the observed number of
recessive genotypes with the empirically estimated counts under the null. This approach
enables a powerful enrichment test while accounting for confounding due to population
stratification and consanguinity [27]. Using this approach, they found recessive variants
are enriched in distinct biological pathways separate from those implicated by other forms
of inheritance and demonstrated that consanguinity is a stronger driver of the recessive
form of birth defects [27].
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More recently, Martin et al. devised a new approach to use the phased haplotypes
from unaffected parents to estimate the expected number of biallelic genotypes in affected probands. Despite methodological differences in these approaches, recent studies
unequivocally suggested that recessive coding variants only account for a small proportion of patients with rare congenital disorders (in the range of 1–4%), compared with
10–20% explained by coding DNVs [27–29]. The large proportion of unexplained patients
even amongst those with affected siblings or high consanguinity suggests that complex
inheritance (e.g., oligogenic and polygenic inheritance, gene–environment interaction) or
other genetic variations (e.g., non-coding regulatory elements or structural variants) await
discoveries using improved genomic technologies and statistical methods in the future.
3.3. Joint Analysis of Transmitted Variants and DNVs
Recent sequencing-based studies have revealed that disease risk genes could be affected by multiple types of genetic variations (e.g., DNVs, transmitted rare variants, or
regulatory variants) [27,44,56]. To accelerate risk gene discovery, several groups have developed a novel statistical framework, known as the Transmission and De novo Association
(TADA) test, to combine information from multiple types of genetic variations or across
multiple genetically correlated disease phenotypes (Table 1). While these tools have been
proven effective, there are some differences and limitations of each TADA variation. We
provide a brief overview below.
The original TADA approach and an extended approach, extTADA, were designed to
incorporate DNVs and transmitted dominant variants in proband-parent trios, as well as
variants identified in unrelated cases and controls for risk gene mapping. A hierarchical
Bayesian strategy is used to rank and test risk genes for a disease of interest [30,31].
However, these approaches fail to consider variants in the non-coding genome. Liu et al.
employed an approach called TADA-Annotations (TADA-A), which combines information
of all DNVs of a gene in both coding and nearby non-coding regions to maximize the
power to detect risk genes [32]. The authors applied TADA-A to WGS data of ~300 ASD
family trios and found that the contribution of de novo non-coding mutations could be
comparable to that of de novo loss-of-function or missense mutations in the coding regions,
which suggests that incorporation of non-coding variants from WGS data can aid risk
gene discovery.
Another limitation of the original TADA approach is that it does not consider the contribution from recessive variants. This limitation has been addressed by TADA-Recessive
(TADA-R), which is built upon TADA to include DNVs, autosomal dominant variants,
and autosomal recessive variants [33]. By applying TADA-R to 2645 congenital heart
disease-affected family trios, Li et al. identified 15 significant genes, half of which are novel,
leading to new insights into the genetic basis of congenital heart disease and once again
highlighting the importance of including recessive variants in genetic studies [33].
The development of multi-trait TADA (mTADA) coincided with the need for the ability
to perform a joint analysis of DNVs from multiple genetically correlated disease traits to
increase the statistical power for risk gene discovery [34]. The mTADA approach uses the
expectation–maximization algorithm to draw associations between the two diseases. By
applying mTADA to large datasets consisting of more than 13,000 trios for five correlated
neuropsychiatric disorders and congenital heart disease, the authors reported additional
risk genes and provided new insights into the shared and disorder-specific biological
mechanisms across these disorders [34].
4. X-Linked Variant Analysis
The sex chromosome constitution is one major source of genetic variation in humans [57]. Moreover, there are many differences in the phenotypes between females, who
typically have two X chromosomes, and males, who typically have one X and one Y chromosome. However, the impact of genetic variations on the sex chromosomes has been
largely overlooked in genetic association studies. Additionally, the complex and dynamic X
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chromosome inactivation (XCI) creates challenges in X-linked variant analyses [35,58]. XCI,
as first described by Ohno et al. in 1959, usually occurs randomly for one of the two X chromosomes in females to equalize dosage of gene products from the X chromosomes between
males and females [59]. Conventional approaches for X-linked variant analysis, such as the
Cochran–Armitage test, assume equal phenotypic effects between males’ hemizygotes and
females’ homozygotes (Table 1) [36]. However, recent studies showed that genes on the
silenced X chromosome can be nonrandomly selected for inactivation and some can escape
from XCI [35,60,61]. Thus, the contingency table approach could lead to a significant power
loss if the underlying biological mechanisms are nonrandom or escaped XCI.
To address this, Wang et al. took various XCI modes (i.e., random, nonrandom, or
escaped XCI) into consideration, and proposed a new statistical approach with greater
statistical power in which 0 or 2 were used for genotype coding in males and 0, d, or 2
were used in females. Here, d quantifies females’ heterogeneous effective allele counts
(Table 1) [35]. Although the improved efficiency and robustness of this approach are
suitable for genome-wide analysis, this method did not consider linkage disequilibrium
(LD) and lacked the ability to adjust for covariates such as age, which is likely to affect the
XCI ratio [37,62,63].
The recent development of very large WES cohorts such as the Deciphering Developmental Disorders project, coupled with the improved understanding of the germline
mutation rate, have enabled more robust estimation of the absolute and relative fraction of
inherited variants and DNVs for complex diseases. Martin et al. conducted sex-specific burden analyses of damaging DNVs to identify an enrichment of specific classes of X-linked
variants in probands and estimated the fraction of probands attributable to those variants [38]. They found that such variants do not fully account for the differential prevalence
between the sexes and that the bulk of X-linked burden is in known developmental disorderassociated genes [38]. More robust X-linked variant analysis and better under-standing of
sex differences in X chromosome biology will require even larger cohorts and integration
of multi-omics data (e.g., RNA-seq or ATAC-seq) that can suggest which X chromosome is
silenced and to what degree a gene is expressed on the inactivated X chromosome.
5. Digenic Variant Analysis
Digenic inheritance (DI) refers to the simplest form of oligogenic inheritance [64]. Individuals with digenic diseases harbor two risk variants at two genomic loci that correspond
to the development of phenotypes that do not segregate in the typical Mendelian inheritance fashion. While thousands of variants have been discovered and linked to monogenic
diseases, only a few hundred were linked to 54 digenic disorders according to the DIDA
database (http://dida.ibsquare.be/, accessed on 17 November 2021). This can be attributed
to several factors, including difficulties in establishing a genotype–phenotype correlation,
reduced penetrance, phenotypic and expression variability, and most importantly, the lack
of efficient and robust methods for detecting gene–gene interaction due to the overall small
effect of each variant on disease risk. The genetic linkage analysis method was successful
in detecting digenic diseases in some families [39], but other methods can be used specially
when the parents’ samples are not available for segregation analysis (Table 1). For example,
the candidate gene approach was very useful in some cases where a gene of interest is
selected to be investigated based on its relevance to the pathway(s) involved in the development of the disease [40]. The approach is quick, cheap, and offers high statistical power.
However, it has been faced with criticisms due to the lack of replication studies and how
much is known about the biological aspect of the investigated disease [65]. Nowadays, the
case-only and machine learning approaches are heavily and continuously developed for
the prediction of digenic diseases.
5.1. Case-Only Approach
The case-only design provides an estimation of gene–gene interactions without requiring negative control samples [66] and demonstrates improved statistical power compared to
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the case–control design [67,68]. Recently, Kerner et al. proposed a genome-wide, case-only
study based on WES data [41]. This approach uses each gene as the unit of analysis and
tests all pairs of genes to detect gene-pair interactions underlying diseases. Furthermore,
Kerner et al. used a classic variant aggregation approach to combine multiple variants
within a gene, and the CAST approach was used to perform burden tests, allowing for
further improved statistical power. The proposed method appears to be simple and flexible
to apply, with a major advantage of the eliminated need for control recruitment. Moreover,
performing hypothesis testing at the gene level greatly reduces the burden of multiple testing and computational time. However, this approach is not robust to gene–gene correlation
(e.g., variants in LD) and will have substantially inflated type I error if the independence
assumption is violated.
5.2. Machine Learning
Although the aforementioned methods have contributed significantly to unraveling
oligogenic diseases, they are often met with limitations and criticism, predominantly due
to their inability to deal with high dimensional data and non-linear regression tests. For
these reasons, machine learning methods started to gain recognition and popularity in the
field of genetics, particularly supervised machine learning where the algorithm predicts
potential gene–gene interaction as an output depending on the input data and the set of
rules obtained through model training. Among the supervised machine learning models,
random forests (RFs), neural networks, cellular automata, and multifactor dimensionality
reduction are the most used [69]. RFs, a tree-based ensemble approach with several
decision-tree classifiers, is especially popular in the field. Where each tree in the forest is
trained with a set of data to predict the outcome, in this context the RFs algorithm would
predict the gene–gene interaction causing the phenotype in question [42]. The Oligogenic
Resource for Variant AnaLysis (ORVAL), which has been used to study digenic diseases, is
also a popular online platform that integrates innovative machine learning methods for
combinatorial variant pathogenicity prediction with visualization techniques [70–73]. The
candidate digenic predictions are then used to rank gene pairs and build an interactive
oligogenic network that can be further explored.
It is understandable that traditional methods alone are unable to detect digenic variants
due to the limitations imposed by the used statistical tests and the often-required preknowledge of biological aspects of diseases. Likewise, limitations can be faced with
the machine learning approach due to insufficient training data, confounding effects,
reproducibility and accessibility, and the potential slow-performing algorithm when dealing
with large data sets [74,75]. Furthermore, the lack of large case–control cohorts hinders
the chances of conforming causative genetic variant combinations. Recent studies on
oligogenic diseases provide evidence of the crucial need to combine genetic analysis
methods along with functional and experimental studies for validation. Li et al. have
provided the first experimental evidence of oligogenic inheritance in heterotaxy, using
sequencing analysis and functional studies on zebrafish and mouse [76]. Additionally,
Gifford et al. published interesting findings of a family with affected children suffering
left ventricular non-compaction cardiomyopathy (LVNC) [77]. In their study, affected
children were found to harbor three genetic variants that were proven to cause LVNC
when combined all together. CRISPR-Cas9 technology and human induced pluripotent
stem cells were used for validation. This suggests that traditional methods alone are not
efficient to detect or confirm the subtle effect of combined genetic variants, and that the use
of advanced gene-editing coupled with in vivo/in vitro approaches is necessary in future
diagnosis of oligogenic diseases.
6. Common Variant Association Analysis
A GWAS aims to identify associations between (typically millions of) SNPs and
a disease or trait of interest. SNP genotypes are usually obtained using a genotyping
microarray for a set of pre-determined variants. The genotype information for each bi-
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allelic SNP is stored as the count of a reference allele, which can be coded as 0, 1, or 2.
It is also a common practice to impute relatively common but ungenotyped SNPs based
on a population haplotype reference panel [78]. A GWAS performs a genome-wide scan
looking for SNPs that are significantly associated with the trait of interest while adjusting
for covariates such as sex, age, and genetic principal components. Due to the large number
of tests in GWAS, the convention is to use a stringent p-value threshold of 5 × 10−8 to
account for multiple testing correction. Different from sequencing-based studies, a GWAS
typically has a larger sample size due to the lower cost of microarray genotyping, but it
is better powered to examine common variant associations than those for variants with
lower frequencies due to poor imputation quality of rare variants, and a lack of ability for
common variants to tag rare variants through LD.
Despite the simplicity, GWAS have identified tens of thousands of associations for
numerous diseases and traits [79]. In particular, the recent emergence of large populationbased biobanks (e.g., UK Biobank [1]) with comprehensive genotype and phenotype data,
coupled with meta-analysis techniques [80] that allow a combination of summary-level
association results across multiple independent cohorts, provides a golden opportunity
for human geneticists to investigate the genetic basis of many human traits. It has been
shown that GWAS-informed genes for disease traits are more likely to be drug targets [81].
Polygenic risk scores (PRS) based on large GWAS have shown substantially improved
prediction accuracy and may have great potential for applications in the clinical setting [82].
GWAS also has some inherent limitations. One major challenge in population-based
GWAS is the unadjusted confounding due to population stratification where different
ancestry groups differ in both variant allele frequencies and the trait under study. In
addition, recent evidence suggests that parental genotypes can be a major confounder for
genetic associations identified in GWAS [83]. A person’s genetic variants exist in both
himself/herself and the biological parents. Thus, these variants can affect a person’s
phenotype both directly (through the inherited genetic variants) and indirectly (through
the parents and the environment they create). GWAS results from a population cohort
are a mixture of both the direct and indirect effects [84]. Because of these limitations,
family-based GWAS, which investigate genotype–phenotype associations within families
(e.g., between siblings), have gained renewed popularity [85]. Within-family GWAS is more
robust to population stratification compared to studies conducted on unrelated individuals.
Leveraging family data with shared environment also improves estimation of direct and
indirect genetic effects, which provides more complete insights into the genetic basis of
human complex traits [85,86]. However, statistical power remains moderate in family-based
GWAS due to the limited number of families even in large biobanks.
Since the proportion of complex trait variance explained by the additive genetic components in GWAS is often smaller than heritability estimated from twin studies, gene–gene
interactions have been hypothesized to partially account for this discrepancy [87,88]. However, testing all pairwise (or higher order) SNP interactions is computationally challenging
and will severely reduce statistical power. Additionally, recent studies suggested very
limited evidence for common SNP epistasis in complex trait genetics [89,90]. However,
a growing literature suggests that both common and rare variants contribute to the risk
of many diseases, and there may be a polygenic background for even rare “Mendeliantype” diseases [91,92]. For example, numerous genes harboring rare pathogenic variants
as well as intergenic regulatory SNPs with higher frequencies have been implicated in
diseases such as congenital heart disease and ASD [27,93–97]. It remains an open question
whether the common, potentially polygenic genetic background can explain the incomplete
penetrance of rare causal variants [98,99]. Increasing samples of WGS data in population
biobanks (e.g., UK Biobank and All of Us) as well as ascertained disease cohorts (e.g.,
Simons Simplex Collection) will provide new opportunities for studying how common and
rare variants jointly shape complex human phenotypes [100].
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7. Disease Risk Prediction
A key goal in human genetic research is to identify individuals at higher disease risks
for early screening and intervention. Thanks to the widely accessible summary-level data
from GWAS, PRS models that can be trained directly using GWAS summary statistics have
quickly gained popularity in recent years. In a nutshell, a PRS is a weighted (by variant
effect sizes) sum of risk allele counts across a (possibly large) number of SNPs. It quantifies
the genetic predisposition of disease risk for an individual and thus can be used to stratify
individuals into high and low risk groups [82].
Methodological challenges in computing PRS reside in estimating the highly polygenic
yet typically weak SNP effects for most complex traits and accounting for extensive LD in
the human genome. Recently, penalized regression models that re-estimate SNP effects from
GWAS summary statistics while explicitly modeling LD have been shown to effectively
improve the predictive performance of PRS [101–103], and novel resampling approaches
now allow model fine-tuning without individual-level genotype and phenotype data [104].
Additionally, Khera et al. convincingly demonstrated that individuals with very high
PRS show substantially elevated coronary artery disease risk that is comparable to having
monogenic mutations with large effects [105]. These studies showcase a promising future
for PRS application in disease prevention and early intervention.
However, challenges remain before clinical use of PRS becomes a reality. Currently,
the vast majority of published GWAS have been conducted on the non-Hispanic white
population [106]. PRS trained from European samples are known to have drastically
reduced prediction accuracy in non-European populations [107]. In addition, substantially
reduced predictive performance has been observed across different demographic groups
even within an ancestry population [108]. Similar reduction of PRS predictive power is also
observed within families (e.g., between siblings), suggesting that a substantial fraction of
genetic association estimated from GWAS may be mediated by the family environments [84].
To better understand the biological mechanisms of genetic associations underlying the
trait-associated loci, it will be critical to distinguish causal effects from environmental (and
familial) confounding, and to explain the lack of portability of PRS between the sexes,
across the social economic status spectrum, and in diverse ancestral populations before we
can appropriately apply PRS to the general populations.
8. Gene Therapy
A primary objective of human genetic studies is to uncover novel genetic etiology
to disease and elucidate pathomechanistic features to develop meaningful therapies for
patients. Among the most-promulgated forms of novel therapies stemming from human
genetic studies is gene therapy, which seeks to alter the biological properties of living
cells by modifying or modulating the gene function and expression in cells [109]. Being
potentially curative, gene therapy has the capacity to spare patients’ years of drug intake in
favor of one-time treatments with lifelong efficacy.
While gene therapy techniques can target both somatic and germline cells, ethical
concerns about introducing heritable changes to humans have prevented the U.S. Food
and Drug Administration (FDA) from approving any therapies targeting germline cells.
Different strategies for different types of diseases have been developed in past decades:
(a) inserting a functional copy of a gene to restore the biological function disrupted by a
deficient copy [110]; (b) providing an interference molecular segment (i.e., small interfering
RNA, suppressor gene, etc.) to inhibit the deficient gene function [111]; (c) correcting the
deficient copy of a gene using genome editing techniques; and (d) adoptively transferring
genetically engineered cells (e.g., hematopoietic stem cells or T cells) to restore or eliminate
the dysfunctional cells [112].
Generally, drug development is divided into five steps: discovery, preclinical research,
clinical research, FDA review, and post-market monitoring. This process is lengthy and
expensive, taking up to 12–15 years with costs of more than USD 1 billion and increasing
every year. At the same time, conventional drug development has slowed exponentially,
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with the number of new drugs brought to market per billion USD spent on research and
development decreasing ten-fold since 1980 and fifty-fold since 1960 [113]. Thus, robust
human genetic studies and integrative multi-omics analyses have become an attractive
high-throughput, hypothesis-free methodology to identify potential targets and explicate
pathomechanisms to better inform drug development [114]. Moreover, these targets feed
into gene therapy development, which, with further study, may present a safe and adaptable
system to provide curative therapies for a variety of genetic disorders. Currently, thousands
of clinical trials for gene therapy targeting different diseases are ongoing in the US, but the
gene therapy technologies are still in a constant state of development and improvement.
In a poignant example of this ‘base pairs-to-bedside’ approach to drug development,
until 2017 sickle cell disease (SCD), one of the most common inherited blood disorders, had
seen no therapeutic innovation to meet unmet clinical needs in over 20 years. Thanks to the
progress of disease association analysis and advanced genetic engineering, more-specific
drugs (i.e., Oxbryta and Adakveo) have become available in the past 3 years [115–117].
Since the SCD phenotype arises from a monogenic defect affecting the β-globin gene [118],
the current strategies for gene therapy treatment are relatively straightforward. The defective β-globin gene function is corrected either by providing a fully functional copy of the
gene or by restoring the expression of the γ-globin gene, a transitory paralog of β-globin
appearing in fetal development. The approach for SCD requires gene modification in
hematopoietic stem cells from the patient followed by transplantation of the functional
cells. An ongoing clinical trial (ClinicalTrials.gov numbers, NCT03282656) showed a
promising outcome, whereby the patient had prompt hematopoietic reconstitution after
treatment [119]. There are many other inherited diseases with FDA-approved gene therapy
treatments, including β-thalassemia [120], amyotrophic lateral sclerosis [121], autosomal
dominant non-syndromic hearing loss [122], hemophilia A and B [123,124], retinal dystrophy [125–129], spinal muscular atrophy [130], and cystic fibrosis [131] (Table 2). With many
more gene therapy treatments still in ongoing development or clinical trials, it is reasonable
to expect significant growth in gene therapy applications as the technology matures and
analytical genomic science further increases successful therapeutic yield.
Table 2. Commercially Available Gene Therapies in the U.S. in Alphabetical Order (2021) [132].
Name

Manufacturer

Target Disease

Gene of Interest

FDA
Approval Date

Abecma
(idecabtagene vicleucel)

Celgene
Corporation
(Bristol-Myers
Squibb Company)

Relapsed or refractory
multiple myeloma

BCMA
(B-cell maturation
antigen)

March 2021 [133]

Breyanzi
(lisocabtagene
maraleucel)

Juno Therapeutics
(Bristol-Myers
Squibb Company)

Relapsed or refractory
large B-cell lymphoma

CD137 (4-1BB TNFreceptor) and CD3-zeta

February 2021 [134]

BioVex
(Subsidiary of Amgen)

Melanoma
(unresectable
cutaneous,
subcutaneous, and
nodal lesions)

GM-CSF (immune
stimulatory protein)

October 2015 [135]

Pediatric B-cell
precursor acute
lymphoblastic
leukemia (ALL)

CD137 (4-1BB TNFreceptor) and CD3-zeta

August 2017 [136]

Relapsed or refractory
large B-cell lymphoma
in adult

CD137 (4-1BB TNFreceptor) and CD3-zeta

May 2018 [136]

Imlygic (talimogene
laherparepvec)

Kymriah
(tisagenlecleucel)

Novartis
Pharmaceuticals
Corporation
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Table 2. Cont.
Name

Manufacturer

Target Disease

Gene of Interest

FDA
Approval Date

Luxturna
(voretigene
neparvovec-rzyl)

Spark
Therapeutics

Retinal dystrophy
(biallelic RPE65
mutationassociated)

RPE65 (human retinal
pigment epithelial 65
kDa protein)

December 2017 [137]

Dendreon
Corporation

Asymptomatic or
minimally
symptomatic metastatic
castration-resistant
prostate
cancer (mCRPC)

ACP3
(prostate acid
phosphatase)

April 2010 [138]

Relapsed or refractory
mantle cell lymphoma
(MCL) in adult

CD28 and CD3-zeta

July 2020 [139]

Relapsed or refractory
B-cell precursor acute
lymphoblastic
leukemia (ALL)
in adult

CD28 and CD3-zeta

October 2021 [139]

Relapsed or refractory
large B-cell lymphoma

CD28 and CD3-zeta

October 2017 [140]

Relapsed or refractory
follicular lymphoma

CD28 and CD3-zeta

March 2021 [140]

Spinal muscular
atrophy (Type I)

SMN1 (human
survival motor neuron
1 protein)

May 2019 [141]

Provenge
(sipuleucel-t)

Tecartus
(brexucabtagene
autoleucel)

Kite Pharma

Yescarta
(axicabtagene
ciloleucel)

Kite Pharma

Zolgensma
(onasemnogene
abeparvovec-xioi)

Novartis Gene
Therapies
(Formerly AveXis)

Licensed gene therapies in the U.S. approved by the Office of Tissues and Advanced Therapies (OTAT) as of
26 October 2021. Name = trade name (proper name); Manufacturer = name of pharmaceutical / biotechnology
company licensed; Target Disease = FDA approved indication(s) excluding disease state(s) in ongoing clinical trials;
Gene of Interest = biological/therapy target (and encoded protein if applicable); FDA approval date = indication
license date based on FDA approval letters.

9. Conclusions
The past decade has been the most fascinating era in the field of human genetics. We
have witnessed unprecedented advances in biotechnologies for high-throughput omics,
the creation of numerous global biobank cohorts with rich genotypic and phenotypic
information, and the emergence of sophisticated statistical and computational methods for
disease gene mapping and risk prediction. In this review, we introduced the state-of-art
methods for research applications based on the study design (i.e., population, or triobased family), genomic technology (i.e., WES, WGS, and GWAS), and the type of genetic
variations under investigation (i.e., de novo, recessive, transmitted, X-linked, and digenic).
We also discussed the current best practices of genomic study in human disorders—gene
therapy—and summarized currently available treatments for diseases (Table 2).
As demonstrated in many studies, genetic variations alter patient responses to clinical
treatments [142–144]. Although much progress has been made in identifying the genetic
etiologies of many complex diseases, additional investigation is required to functionally
connect most genetic variants with disease phenotypes through molecular pathomechanisms. The advent of GWAS/WES and, more recently, WGS has equipped molecular
geneticists with the tools needed to decipher the genetic etiologies of rare and complex
diseases. Current multi-omics studies using single-cell RNA-sequencing, ChIP-seq, and
ATAC-seq have revealed more comprehensive complex biological molecules involved in
the structure, function, and dynamics of a cell, tissue, or organism (reviewed in Ref. [145]).
The integration of these novel technologies presents new hope in explicating the functional
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impact of many disease risk variants and the genetic pathology of complex disease traits.
For many patients, this represents the end of a lifelong diagnostic odyssey preventing them
from receiving precision therapy, understanding their prognosis, and making important
life-planning decisions.
Many in the field speculate that, as WES/WGS becomes increasingly more common
and affordable, increased understanding of variant–phenotype relationships and novel
integrative genomic and pharmacogenomic therapeutic approaches tailored to patientspecific genetic information may revolutionize clinical care by increasing treatment specificity [146,147]. Quantitative phenomics is a critical component of the evolving integrative
genomic approach. Standardized human phenotype annotation databases [148,149] and
novel phenotype clustering algorithms [150,151] are developing to enable much more
comprehensive and intelligent phenomics analysis. Transitioning to high quality, electronic, and increasingly standardized phenomics information can improve the phenotypic
characterization of various heterogeneous disorders and identify associations between
certain genetic variants and their respective clinical outcomes or presentation. This thereby
provides better prognostication and clinical management, particularly of disorders with
highly varied and poorly differentiated intra-disorder phenotypes [152,153]. Incorporating
patient genetic information into clinician-friendly data platforms (i.e., electronic medical
records) will maximize drug efficacy and minimize adverse effects, enriching precision
medicine in practice [154]. The interface between genomic information and electronic
health records coupled with increasingly improved methods can facilitate more precise
discovery of genetic variants to guide more accurate therapeutic decisions in the future.
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